

EVOTEC AG

ISIN: DE0005664809 WKN: 566480 Asset Class: Stock

Company 2023/03/29 17:35:26

Price
19.11
 EUR

Difference ↑
 2.06%(0.39)



Contact Details

EVOTEC SE
 --
 Manfred Eigen Campus, Essener
 Bogen 7
 22419 Hamburg

Tel: +49-40-56081-0
 Fax: +49-40-56081-222
 Web: <http://evotec.com>
 E-mail: info@evotec.com

Company Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Financial figures

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	1,100,940,000		658,844,000		469,530,000	
Common stock capital		176,608,000		163,915,000		150,903,000
Fixed assets	1,175,323,000		843,633,000		759,738,000	
Equity capital of a company		1,377,685,000		722,846,000		477,029,000
Cash and cash equivalents	699,326,000		422,580,000		277,034,000	
Accrued liabilities		18,021,000		22,899,000		22,538,000
Other assets	-		-		-	
Current liabilities		324,516,000		208,459,000		178,955,000
Prepayments and accrued income		-		-		-
Non-current liabilities		574,062,000		571,172,000		573,284,000
Different income		-		-		-
Other liabilities		34,943,000		26,335,000		38,823,000
Total assets	2,276,263,000	2,276,263,000	1,502,477,000	1,502,477,000	1,229,268,000	1,229,268,000

Balance notes

	2021	2020	2019
Accounting standard	IFRS	IFRS	IFRS
Employees	4,198	3,572	3,030
Equity ratio	60.52%	48.11%	38.81%
Debt-equity ratio	65.22%	107.86%	157.69%

Others

	2021	2020	2019
Tax Expense Rate	-4.75%	-52.04%	-29.11%

Income statement

	2021	2020	2019
Turnover	618,034,000	500,924,000	446,437,000
Net income	215,510,000	6,252,000	38,072,000
EBIT	228,532,000	18,101,000	35,729,000
Operating income before taxes	221,550,000	10,975,000	30,545,000
Cash Flow	122,237,000	44,721,000	42,216,000
Net interest income	-6,982,000	-7,126,000	-5,184,000
Research and development expenses	72,200,000	63,945,000	58,432,000
Income taxes	-10,530,000	-5,711,000	-8,893,000
Result from investments in subsidiaries, associates and other	-16,570,000	-10,434,000	-2,210,000
Revenues per employee	147,221	140,236	147,339

Board of Directors

Iris Löw-Friedrich	Chairman of Supervisory Board
Constanze Ulmer-Eilfort	Member of Supervisory Board
Elaine Sullivan	Member of Supervisory Board
Mario Polywka	Member of Supervisory Board
Camilla Languille	Member of Supervisory Board
Roland Sackers	Member of Supervisory Board

Members of Management Board

Werner Lanthaler	Chairman of Managing Board
Cord Dohrmann	Member of Executive Committee
Craig Johnstone	Member of Executive Committee
Enno Spillner	Member of Executive Committee